Human Health Advise Solution ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
Loading...

Loading...

Loading...

Loading...

Loading...

Loading...

Loading...

Bankruptcy Risk 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Bankruptcy risk for industry  2.7% 2.7% 2.7% 2.7% 2.7%  
Bankruptcy risk  19.4% 14.5% 12.5% 12.7% 12.1%  
Credit score (0-100)  7 14 17 17 19  
Credit rating  B BB BB BB BB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6

Net sales  0 0 0 0 0  
Gross profit  -10.3 -54.9 -6.9 -4.1 -1.6  
EBITDA  -10.3 -54.9 -6.9 -4.1 -1.6  
EBIT  -10.3 -54.9 -6.9 -4.1 -1.6  
Pre-tax profit (PTP)  -10.3 -54.9 -7.0 -4.4 -1.6  
Net earnings  -7.6 -40.5 -5.5 -3.5 -1.3  
Pre-tax profit without non-rec. items  -10.3 -54.9 -7.0 -4.4 -1.6  

 
See the entire income statement

Balance sheet (kDKK) 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  72.4 39.5 33.8 30.3 29.0  
Interest-bearing liabilities  0.5 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  75.0 39.5 33.8 30.3 29.0  

Net Debt  -69.8 -18.7 -12.2 -12.3 -11.6  
 
See the entire balance sheet

Volume 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  -10.3 -54.9 -6.9 -4.1 -1.6  
Gross profit growth  -6,785.3% -431.3% 87.4% 40.8% 59.7%  
Employees  0 0 0 0 0  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  75 39 34 30 29  
Balance sheet change%  -6.0% -47.4% -14.4% -10.3% -4.6%  
Added value  -10.3 -54.9 -6.9 -4.1 -1.6  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  -2.0 -3.0 -4.0 -5.0 -5.0  

Profitability 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  100.0% 100.0% 100.0% 100.0% 100.0%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  -13.3% -95.8% -19.2% -13.9% -5.6%  
ROI %  -13.5% -97.7% -19.2% -13.9% -5.6%  
ROE %  -9.9% -72.5% -15.0% -10.8% -4.3%  

Solidity 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Equity ratio %  96.5% 100.0% 100.0% 100.0% 100.0%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  675.7% 34.1% 176.4% 300.5% 702.0%  
Gearing %  0.7% 0.0% 0.0% 0.0% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 0.0% 0.0% 0.0%  

Liquidity 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Quick Ratio  28.6 0.0 0.0 0.0 0.0  
Current Ratio  28.6 0.0 0.0 0.0 0.0  
Cash and cash equivalent  70.3 18.7 12.2 12.3 11.6  

Capital use efficiency 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  75.9 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  72.4 39.5 33.8 30.3 29.0  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 0  
EBIT / employee  0 0 0 0 0  
Net earnings / employee  0 0 0 0 0